Woon Keat Moh
Known title: SVP, President CAI Asia & AmerCIK: 0001796125
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Avient Announces New CEO Mike Frank, Reaffirms Guidance. Avient disclosed that Mike Frank will assume the chief executive role, succeeding Dr. Ashish Khandpur. The company kept its FY2026 adjusted EPS outlook of $3.10‑$3.25 and its Q3 adjusted EPS guidance of $0.80. The leadership change was highlighted alongside a dividend champion note, and the stock fell about 7% after the news. The announcement arrives as the shares trade near a long‑standing support level.
Transaction History
| ROG | ▲ Buy | Grant | 1,427 | $0 | 5/6/2026 | View on chart |
| AVNT | ▲ Buy | Option Exercise | 2,280 | — | 2/19/2026 | View on chart |
| AVNT | ▼ Sell | Tax Withholding | 1,260 | $54K | 2/19/2026 | View on chart |
| AVNT | ▼ Sell | Tax Withholding | 2,267 | $98K | 2/17/2026 | View on chart |
| AVNT | ▲ Buy | Option Exercise | 3,900 | — | 2/17/2026 | View on chart |
| AVNT | ▲ Buy | Option Exercise | 1,870 | $47K | 1/20/2026 | View on chart |
| AVNT | ▼ Sell | Tax Withholding | 1,618 | $58K | 1/20/2026 | View on chart |
| ROG | ▲ Buy | Grant | 2,760 | $0 | 5/5/2025 | View on chart |
| AVNT | ▲ Buy | Option Exercise | 3,300 | — | 2/14/2025 | View on chart |
| AVNT | ▼ Sell | Tax Withholding | 1,907 | $82K | 2/14/2025 | View on chart |
| ROG | ▲ Buy | Grant | 536 | $0 | 1/1/2025 | View on chart |
| AVNT | ▲ Buy | Option Exercise | 1,250 | $48K | 12/11/2024 | View on chart |
| AVNT | ▼ Sell | Tax Withholding | 1,121 | $55K | 12/11/2024 | View on chart |
| AVNT | ▲ Buy | Option Exercise | 3,450 | — | 2/8/2024 | View on chart |
| AVNT | ▼ Sell | Tax Withholding | 1,982 | $73K | 2/8/2024 | View on chart |
| AVNT | ▲ Buy | Option Exercise | 3,900 | — | 2/10/2023 | View on chart |
| AVNT | ▼ Sell | Tax Withholding | 2,243 | $85K | 2/10/2023 | View on chart |
| AVNT | ▲ Buy | Option Exercise | 1,683 | — | 2/11/2022 | View on chart |
| AVNT | ▼ Sell | Tax Withholding | 951 | $50K | 2/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Roche presents new Phase III data and FDA approval
Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.
Roche presents new Phase III data and FDA approval. Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.